Share:
The Liver Meeting, organised by the American Association for the Study of Liver Diseases, was held as a hybrid event on 15-19 November 2024 in San Diego, California, United States of America.
Highlights in the field of chronic hepatitis B, C and D research: official company press releases
- Barinthus Bio announces results from ongoing Phase 2b chronic hepatitis B trial, including achievement of functional cure and HBsAb seroconversion
- Arbutus and Barinthus Bio announce new data from the IM-PROVE II trial showing that the addition of nivolumab increased rates of HBsAg loss in people with chronic hepatitis B
- Arbutus’ imdusiran achieves functional cure in cHBV patients when combined with a short course of interferon
- Vir Biotechnology announces positive end-of-treatment results for tobevibart and elebsiran combinations in chronic hepatitis B from the MARCH study at AASLD The Liver Meeting
- Vir Biotechnology presents positive chronic hepatitis delta clinical trial data and announces initiation of Phase 3 registrational program
- Aligos Therapeutics presents positive data at The Liver Meeting 2024
- Precision BioSciences highlights preclinical data and outlines design of first-in-human clinical trial for PBGENE-HBV for treatment of chronic hepatitis B
- Atea Pharmaceuticals presents multiple new datasets supporting the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus at AASLD’s The Liver Meeting 2024
- Brii Bio delivers first head-to-head comparison of siRNA (elebsiran) and PEG-IFNα combination versus PEG-IFNα alone at AASLD’s The Liver Meeting® 2024, demonstrating higher loss of HBV surface antigen by combining with siRNA
- SCG Cell Therapy presents promising Phase 1 data for a novel HBV-specific TCR-T therapy (SCG101) at the AASLD Liver Meeting 2024
- Virion Therapeutics reports first-ever clinical responses with VRON-0200, a novel checkpoint modifier for HBV functional cure, at AASLD’s The Liver Meeting®
- AASLD 2024: Tune Therapeutics shows near-complete hepB virus repression with Tune-401 epigenetic silencer
- Bluejay Therapeutics reports best-in-class monoclonal antibody BJT-778 achieved 100% virologic response and up to 78% combined virologic response and ALT normalization as monotherapy in participants with chronic hepatitis D (CHD)
———————
Reports from Healio: all reports can be accessed here
Selected highlights:
- Combination PEG-INF a-2b therapy achieves higher HBsAg loss in HBV-infected children
- VIDEO: Combination tobevibart, elebsiran induces ‘rapid virologic suppression’ in HDV
- VIDEO: HBsAg loss with tobevibart, elebsiran combination ‘highly promising’ in chronic HBV
- Resuming antiviral therapy after withdrawal does not affect HBsAG seroclearance in HBV
———————
Reports from HCPLive: all reports can be accessed here
Selected highlights:
- VTP-300, nivolumab combination shows promise for functional HBV cure in Phase 2b trial
- Telehealth could address HCV care barriers, expand treatment for people who inject drugs
- Chari Cohen, DrPH, MPH: Healthcare providers’ role in HBV clinical trial diversity
———————
Reports from Gastroenterology Advisor: all reports can be accessed here
Selected highlights:
- Tenofovir alafenamide associated with improved liver outcomes in chronic hepatitis B
- Chronic hepatitis B treatment access differs between men and women
- Alternative HBV vaccination strategies improve protection in patients with cirrhosis
———————
Reports from Contagion Live
Selected highlights:
- Imdusiran for chronic hepatitis B achieves functional cure in 50% of patients
- Investigational combination hepatitis C therapy demonstrates a 97% sustained virologic response
- Investigational hepatitis D monoclonal antibody achieves 100% virologic response
———————
Reports from NATAP: all reports can be accessed here.
———————
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.